CPT Code 80305: Presumptive drug class screening billing guide

Key Takeaways

CPT Code 80305 covers presumptive drug class screening using direct optical observation, identifying drug class presence, not a specific drug.

80305 applies to point-of-care testing with immediate visual results; codes 80306 and 80307 cover higher-complexity presumptive methodologies requiring instrumented readers or chromatography.

Missing medical necessity documentation is the most common denial reason: the ordering provider, clinical indication, test result, and date of service must all appear in the chart.

Practice management software like Pabau ties structured clinical documentation to billing, reducing 80305 denials caused by missing chart evidence.

CPT Code 80305: Definition and clinical description

CPT Code 80305 is the billing code for presumptive drug class screening performed by direct optical observation. According to the AMA CPT code set, this method detects the possible presence or absence of a drug class, not a specific drug or its metabolite.

The result is typically read visually by the provider at the point of care, making it one of the fastest testing methods available in a clinical setting.

This code sits within the Chemistry subsection of the Pathology and Laboratory chapter of the CPT manual. It is used most frequently in pain management clinics, primary care practices, and addiction medicine settings where rapid, in-office results are needed to guide clinical decisions.

CPT Code 80305 description and key facts

The table below summarizes the core reference data for 80305. These details appear consistently across the AMA CPT manual and CMS billing guidance.

One important distinction: 80305 covers any number of drug classes tested in a single encounter using direct optical observation. You do not submit one unit per drug class tested. The code is billed once per date of service for the optical observation methodology, regardless of how many classes the panel screens for.

Presumptive vs definitive drug testing: Understanding the difference

Choosing the wrong code between presumptive and definitive testing is one of the most frequent coding errors in urine drug testing billing. The distinction matters clinically and financially.

Presumptive testing identifies the possible presence of a drug class. It does not confirm a specific substance or its concentration. Definitive testing, by contrast, uses chromatography or mass spectrometry to identify and quantify specific drugs and metabolites. These are different procedures with different reimbursement rates and different documentation requirements.

CPT codes 80305, 80306, and 80307 compared

All three codes describe presumptive drug testing, but each covers a different testing methodology. The methodology determines which code applies, not the number of drug classes screened.

If the provider reads the test strip visually without an electronic device, the correct code is 80305. Using 80306 or 80307 for a visual read is upcoding and a common audit flag. Review your practice’s digital medical forms to confirm the testing methodology is recorded at each encounter.

Medicare reimbursement and fee schedule for CPT Code 80305

CPT Code 80305 is priced under the Medicare Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. As a clinical laboratory test, it is paid at a single national rate: there are no relative value units (RVUs), no facility versus non-facility split, and no geographic or locality adjustment.

Always verify the current rate using the CMS fee schedule, since CMS updates CLFS rates periodically throughout the year.

Because 80305 carries a modest reimbursement, each denial erodes the margin on time already invested in testing and documentation. Practices running high volumes of point-of-care drug screens in addiction medicine or pain management should treat accurate code selection as a priority, not an afterthought.

For additional context on Medicare reimbursement management across your practice, time-saving practice features often include automated coding workflow tools.

Place of service for CPT Code 80305

Because CPT Code 80305 is priced on the Clinical Laboratory Fee Schedule, place of service (POS) codes do not change the Medicare reimbursement rate. Unlike codes priced on the Physician Fee Schedule, there is no facility versus non-facility rate differential to manage for 80305.

The POS code submitted on the claim should still accurately reflect where the test was performed and read, for compliance, audit, and CLIA-certificate documentation purposes.

• POS 11 (Office): The most common setting for point-of-care 80305 screens; the test is performed and read on-site
• POS 19 (Off Campus-Outpatient Hospital): Test performed at an off-campus hospital outpatient department
• POS 22 (On Campus-Outpatient Hospital): Test performed at an on-campus hospital outpatient department
• POS 50 (Federally Qualified Health Center): FQHCs follow their own encounter-based billing rules in addition to standard CLFS billing
• POS 72 (Rural Health Clinic): RHCs similarly follow their own encounter-based billing rules alongside standard CLFS billing

Billing guidelines and documentation requirements for urine drug testing CPT codes

Missing documentation is the top reason CPT Code 80305 claims are denied. Under CMS billing guidelines, urine drug testing claims require specific chart evidence to establish medical necessity. The ordering provider is responsible for ensuring this documentation exists before the claim is submitted.

The following elements must appear in the medical record for each date of service where 80305 is billed:

• Ordering provider identity: Name, credentials, and National Provider Identifier (NPI) of the provider who ordered the test
• Clinical indication: The reason testing was clinically necessary, tied to a documented diagnosis or treatment plan
• Date of service: The specific date the test was performed and the result was read
• Test result: The outcome of the visual read, including which drug classes were screened and the positive/negative result for each
• Response to result: Some payer Local Coverage Determinations (LCDs) require documentation of how the result affected clinical decision-making

Practices operating under HIPAA are also required to maintain drug testing records in a manner consistent with protected health information rules. For practical guidance on record-keeping obligations, see HIPAA compliance guidance. Maintaining secure patient data storage across all clinical documentation systems is equally important when drug testing records are subpoenaed or audited.

ICD-10 codes that support medical necessity for 80305

Selecting an appropriate ICD-10 diagnosis code is critical for demonstrating medical necessity. The diagnosis code must reflect the patient’s documented clinical condition. Always verify which ICD-10 codes your specific payer’s LCD accepts, because coverage policies vary by MAC jurisdiction and payer.

The table below lists codes most commonly paired with 80305 in pain management and substance use disorder settings. Panels that also screen for alcohol use a separate diagnosis code, Y90.9, rather than one of the drug-specific codes below.

Note: The ICD-10 codes above are subject to payer policy. Coverage is not guaranteed by the presence of any specific diagnosis code. Reference the applicable LCD for your MAC jurisdiction and verify coverage with each payer before submitting.

For practices managing patients with mental health and substance use diagnoses, psychiatry EMR software platforms can help structure documentation so the clinical indication is consistently captured at every encounter.

Related HCPCS codes: G0480 and G0481

While CPT Code 80305 covers presumptive testing, some payers use HCPCS G-codes for definitive drug testing in certain coverage contexts. G0480 and G0481 are CMS-maintained HCPCS codes that function as alternatives to the CPT definitive drug testing codes (80320-80377) in specific payer scenarios.

G0480 and G0481 are not universal substitutes for the CPT definitive drug testing codes. Their use depends on the payer and the date of service. Medicare Advantage plans and some Medicaid managed care organizations may require G-codes rather than CPT codes for definitive testing.

Always confirm with the specific payer before submitting. For coding validation across your drug testing workflow, review the AAPC CPT code reference alongside your payer contracts.

Cut denials on drug testing claims

Pabau links structured clinical notes directly to your billing workflow, so missing 80305 documentation is caught before the claim leaves your practice. See how it works with a live demo.

Book a demo

Common billing errors and how to avoid them

CPT Code 80305 generates a disproportionate share of urine drug testing denials despite being the simplest code in the family. Most errors fall into four categories.

• Upcoding to 80306 or 80307: Submitting an instrumented or higher-complexity code when the test was visually read. Auditors look at the testing device documented in the chart. If no reader device is documented, 80305 is the only defensible code.
• Missing medical necessity: The chart contains the test result but no clinical indication explaining why the test was ordered. Payer LCDs require a documented reason tied to the patient’s treatment plan.
• Unbundling definitive testing: Billing 80305 alongside definitive CPT codes (80320-80377) on the same date of service may trigger edits if payers apply National Correct Coding Initiative (NCCI) bundling rules. Confirm with each payer whether presumptive and definitive testing are separately billable on the same DOS.
• Incorrect date of service: The date billed must match the date the test was performed and read, not the date the order was placed or the result was reviewed by the provider at a later encounter.

Practices using primary care HIPAA workflows typically have better documentation habits that translate directly into lower denial rates. Structured intake and ordering workflows force coders to record methodology, indication, and result together, so nothing is missing at claim time. For a broader look at HIPAA compliance across practices, the rules are consistent: documentation must be complete before the claim leaves.

Clinical settings where CPT Code 80305 is commonly used

Point-of-care drug screening via direct optical observation fits naturally into several clinical contexts where rapid results affect immediate clinical decisions. Understanding where 80305 is most frequently billed helps coders verify that the methodology documented matches the setting.

• Pain management clinics: Monitoring compliance with controlled substance agreements. Patients on long-term opioid therapy are typically screened at every visit. The Z79.891 (long-term opiate use) or G89.29 (chronic pain) diagnosis codes most often support medical necessity here.
• Addiction medicine and SUD treatment programs: Weekly or biweekly point-of-care screens are standard practice in outpatient opioid treatment programs (OTPs) and medication-assisted treatment (MAT) clinics, alongside procedures such as buprenorphine implant insertion, billed under CPT 11981. The speed of visual reading is operationally important when results inform same-day dosing decisions.
• Primary care practices: Increasingly common when managing patients on controlled substances for chronic conditions. A primary care physician monitoring a patient’s benzodiazepine or stimulant use will often use 80305 as a low-complexity, in-office screen.
• Behavioral health practices: Co-occurring substance use and mental health disorders make drug monitoring part of routine care, including in residential programs billed under HCPCS H0019. Functional medicine software supporting complex patient populations may also incorporate point-of-care screens into wellness monitoring protocols.

In all of these settings, drug screening adds to the administrative load on clinical staff. For practices managing high volumes of screens alongside busy appointment schedules, administrative workload is a driver of clinician burnout. Streamlining the documentation-to-billing pathway reduces this burden without adding risk to claim accuracy.

How practice management software supports drug testing billing

A clean point-of-care drug screen only becomes a paid claim when the documentation behind it is complete. Missing information, not the test itself, is almost always the reason 80305 claims get denied.

Pabau addresses this by connecting structured clinical note-taking directly to the billing workflow, so the fields required to support CPT Code 80305 are captured at the moment of care rather than reconstructed later.

When a provider runs an 80305 screen in Pabau, the clinical record captures the ordering provider, the date and time, the methodology, the drug classes screened, and the result. That data feeds directly into the billing workflow, so a coder doesn’t have to chase the chart for missing information before the claim goes out.

For practices managing end-to-end practice management across multiple providers or locations, this consistency matters: documentation habits vary by clinician, and a centralized system keeps the record complete regardless of who’s charting.

For coders looking to stay current on drug testing procedure codes, the broader CPT code reference library on Pabau covers related procedure types.

Keeping records audit-ready applies directly here: outdated or incomplete records are the fastest route to a denied 80305 claim. Practices that treat documentation as an afterthought consistently see higher denial rates than those that embed it into the clinical workflow from the start.

Continue your research

Billing for supply items alongside a drug screen? HCPCS A4250 covers over-the-counter pregnancy test kits sometimes billed alongside a drug screen.

Building out a substance use disorder program? Pabau’s substance abuse treatment plan template helps structure the clinical documentation that supports medical necessity.

Screening patients before starting opioid therapy? The Opioid Risk Tool template supports the risk assessment that often accompanies ongoing drug monitoring.

Conclusion

Most CPT Code 80305 denials trace back to one of two fixable problems: the wrong code was selected because the methodology was not documented, or the claim lacked a recorded clinical indication. Both are documentation problems, not coding problems.

Pabau’s structured clinical workflows capture the methodology, indication, and result at point of care, feeding them directly into the billing workflow through EHR integration. If your 80305 denial rate is climbing, start with a documentation audit before changing your coding process.

Frequently asked questions